Segment Information |
Note 8 - Segment Information
Prior to the November 2013 acquisitions of TempSys and Amega, we had two reporting segments: Biological Indicators and Instruments. As a result of these acquisitions we added a third reporting segment, Continuous Monitoring. The following tables set forth our segment information (in thousands):
|
|
Three Months Ended December 31, 2013 |
|
|
|
Biological
Indicators |
|
Instruments |
|
Continuous
Monitoring |
|
Total |
|
Revenues |
|
$ |
5,317 |
|
$ |
6,438 |
|
$ |
1,361 |
|
$ |
13,116 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
$ |
2,976 |
|
$ |
4,137 |
|
$ |
593 |
|
$ |
7,706 |
|
Selling expenses |
|
404 |
|
1,047 |
|
144 |
|
1,595 |
|
|
|
$ |
2,572 |
|
$ |
3,090 |
|
$ |
449 |
|
6,111 |
|
Reconciling items (1) |
|
|
|
|
|
|
|
(3,384 |
) |
Earnings before income taxes |
|
|
|
|
|
|
|
$ |
2,727 |
|
|
|
Three Months Ended December 31, 2012 |
|
|
|
Biological
Indicators |
|
Instruments |
|
Continuous
Monitoring |
|
Total |
|
Revenues |
|
$ |
5,154 |
|
$ |
6,207 |
|
— |
|
$ |
11,361 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
$ |
2,936 |
|
$ |
4,011 |
|
— |
|
$ |
6,947 |
|
Selling expenses |
|
385 |
|
838 |
|
— |
|
1,223 |
|
|
|
$ |
2,551 |
|
$ |
3,173 |
|
— |
|
5,724 |
|
Reconciling items (1) |
|
|
|
|
|
|
|
(3,298 |
) |
Earnings before income taxes |
|
|
|
|
|
|
|
$ |
2,426 |
|
|
|
Nine Months Ended December 31, 2013 |
|
|
|
Biological
Indicators |
|
Instruments |
|
Continuous
Monitoring |
|
Total |
|
Revenues |
|
$ |
16,181 |
|
$ |
19,468 |
|
$ |
1,361 |
|
$ |
37,010 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
$ |
9,019 |
|
$ |
12,491 |
|
$ |
593 |
|
$ |
22,103 |
|
Selling expenses |
|
1,350 |
|
2,603 |
|
144 |
|
4,097 |
|
|
|
$ |
7,669 |
|
$ |
9,888 |
|
$ |
449 |
|
18,006 |
|
Reconciling items (1) |
|
|
|
|
|
|
|
(9,326 |
) |
Earnings before income taxes |
|
|
|
|
|
|
|
$ |
8,680 |
|
|
|
Nine Months Ended December 31, 2012 |
|
|
|
Biological
Indicators |
|
Instruments |
|
Continuous
Monitoring |
|
Total |
|
Revenues |
|
$ |
15,590 |
|
$ |
18,037 |
|
— |
|
$ |
33,627 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
$ |
8,890 |
|
$ |
11,761 |
|
— |
|
$ |
20,651 |
|
Selling expenses |
|
1,165 |
|
2,132 |
|
— |
|
3,297 |
|
|
|
$ |
7,725 |
|
$ |
9,629 |
|
— |
|
17,354 |
|
Reconciling items (1) |
|
|
|
|
|
|
|
(8,290 |
) |
Earnings before income taxes |
|
|
|
|
|
|
|
$ |
9,064 |
|
(1) Reconciling items include general and administrative, research and development, and other expenses.
|
|
December 31, 2013 |
|
March 31, 2013 |
|
Total assets |
|
|
|
|
|
Biological Indicators |
|
$ |
25,710 |
|
$ |
27,558 |
|
Instruments |
|
33,759 |
|
31,782 |
|
Continuous Monitoring |
|
28,485 |
|
— |
|
Corporate and administrative |
|
4,601 |
|
6,579 |
|
|
|
$ |
92,555 |
|
$ |
65,919 |
|
All long-lived assets are located in the United States.
Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows (in thousands):
|
|
Three Months Ended
December 31, |
|
Nine Months Ended
December 31, |
|
|
|
2013 |
|
2012 |
|
2013 |
|
2012 |
|
Net revenues from unaffiliated customers: |
|
|
|
|
|
|
|
|
|
United States |
|
$ |
7,054 |
|
$ |
7,013 |
|
$ |
20,877 |
|
$ |
20,504 |
|
Foreign |
|
6,062 |
|
4,348 |
|
16,133 |
|
13,123 |
|
|
|
$ |
13,116 |
|
$ |
11,361 |
|
$ |
37,010 |
|
$ |
33,627 |
|
No foreign country exceeds 10% of total revenues.
|